Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas - Wikidata - awgldk - TriplyDB

Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas

Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas

http://www.wikidata.org/entity/Q35018167

about

Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy Patterns of gene expression and DNA methylation in human fetal and adult liver.EGFR promoter exhibits dynamic histone modifications and binding of ASH2L and P300 in human germinal matrix and gliomas.Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.Transcriptional control analyses of the Xiphophorus melanoma oncogene.RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb.The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma.Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools.FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer FOXC1 promotes melanoma by activating MST1R/PI3K/AKT.A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants.Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma.A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.Epigenetic regulation of RTK signaling.Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma.Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.Comparison of Xiphophorus and human melanoma transcriptomes reveals conserved pathway interactions.miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway.3-O-acetyl-11-keto-β-boswellic acid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/M phase.

P2860

Q26778761-24B86959-3CBF-4776-83DC-2063E557C362 Q26783032-0692D830-B5C1-4E99-AA73-381B9C31A6D9 Q35847505-2F6492DF-618E-4730-9A98-95972A6F9885 Q36214341-28F2D352-7B1F-4CAB-B8B4-720C9669F859 Q36260662-08C7F922-BDA6-4836-963A-8C2D3538E09F Q36327541-32666198-610D-4E64-8B9A-4D9349FF5169 Q36557527-E468C2CC-3184-4C7D-BBE7-116AACD39BB5 Q37301914-823AA427-66BA-4E97-AABD-0EC48A47CBBA Q37418541-BAA492A6-7939-4CB8-A9E7-59BC5A30C4FB Q37609227-FDCAAF2E-0E40-45EF-AA36-B8CB052E3EE9 Q37708952-5FC60372-AA9F-47DB-B8DB-A63FF5276193 Q38683823-84D18F7D-A648-434A-9D33-1F1C853C3CE5 Q38813507-CFDB9654-921A-44D7-86D1-395F16749202 Q38847201-99DC514A-629C-4777-9905-6BA9A031BFCD Q38903238-38DDE6B0-A385-42D0-9678-2DC862D9D651 Q39356240-91D33E57-9923-4A57-BC90-0C05E630B369 Q39434922-20D287BC-22EF-4A11-AE08-835EBAA75496 Q42369856-EDAF7068-7958-46A4-893C-200163926533 Q47325071-E532118C-272D-488F-B924-8FCBD25B06A0 Q47566725-F0B1DBA3-6BA8-4A78-BCF4-E9B1188F5C69 Q48279436-B48E5A1F-135D-4482-A5B9-D417A0F576E1 Q55352295-92F62E7A-8DA3-42BD-9AAE-9B49A7B78E9D Q55517828-D1653E04-CF97-44FB-B32A-556BA9D49847

P2860

Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas

http://www.wikidata.org/entity/Q35018167

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Epigenetic changes of EGFR hav ...... -resistant cutaneous melanomas

@ast

Epigenetic changes of EGFR hav ...... -resistant cutaneous melanomas

@en

type

label

Epigenetic changes of EGFR hav ...... -resistant cutaneous melanomas

@ast

Epigenetic changes of EGFR hav ...... -resistant cutaneous melanomas

@en

prefLabel

Epigenetic changes of EGFR hav ...... -resistant cutaneous melanomas

@ast

Epigenetic changes of EGFR hav ...... -resistant cutaneous melanomas

@en

P1433

Q35018167-2AD9165A-BF67-4C53-9201-490EB2E1B941

P1476

Q35018167-949A10DA-3BB7-4057-82EB-E8575B5908D9

P2093

Q35018167-14D7EE83-9044-4516-BF01-6431DCB40D1A

Q35018167-3912A29B-1D7D-4883-B6E7-CB4EB5CDC1C6

Q35018167-56301586-9F75-40CA-95EC-E4A6C1E8DBC3

Q35018167-73089343-E36E-48B1-A64D-194310C8A61E

Q35018167-7E13BDB8-DB25-4EFC-9EE2-E1EA9BCB7297

Q35018167-859ADD1C-26B9-4BCA-AB55-931292E1495B

Q35018167-874CF013-12E8-4884-93ED-4449782D2417

Q35018167-ECF3F2B3-9D76-4DCD-9BCF-8D6A4693593B

P2860

Q35018167-015B2E59-C7E9-4CC4-98D8-8D49891B32AF

Q35018167-0404B5CA-93B0-426C-BB2F-91279FC7135B

Q35018167-06CA9BB8-33E6-4F7F-8605-F2251FDC223E

Q35018167-184DC014-E626-41B2-BF17-1EC475110D1D

Q35018167-25C486D6-840A-4FD8-8720-90F1ABFC82B5

Q35018167-262762C4-AF5A-4210-9187-80B40DF2015C

Q35018167-2852E158-C44B-4BE7-BFCC-0DAAE751CB01

Q35018167-2A3BAAA3-C3AC-4B53-BBE3-6EEB32D01514

Q35018167-2B989893-234A-48D8-A7B3-322D14D03145

Q35018167-2F5EC6B4-5616-4D99-96A9-3F050FDF8C1A

P2888

Q35018167-96FF3B3C-DE8F-4CDB-939C-6DA4598B1DED

P304

Q35018167-287C4D8E-D187-4000-9CD2-1A453E6F101C

P31

Q35018167-F1FA46DE-3393-4818-B62C-4BE6E6BBCB30

P356

Q35018167-37CEAAAB-CAA5-4693-9F8A-15645282363E

P407

Q35018167-8F0C677F-0D5F-455B-9A3E-F368E52ACF93

P433

Q35018167-F937E93C-8330-438E-9081-689FD02841C9

P478

Q35018167-EB4EB522-364F-4CC6-A797-2AA498310C5E

P50

Q35018167-542D41F6-3BF3-4829-BBF7-2E4B11CB97E7

Q35018167-6EBDC28B-F9CD-4CBB-9681-CDA8EE597C9E

Q35018167-7F9AA320-DEDD-4BB6-85AD-34FED3D3DE14

Q35018167-A2A1607C-CD3D-4D43-9CCC-8FFB09825E85

Q35018167-C62E6047-26E1-4955-806D-52D8CD6C2EB8

P577

Q35018167-6E504626-D669-499D-A09B-CE90D631AAD3

P5875

Q35018167-D2DD23FA-68C8-49E5-8D11-3F8A6A615389

P698

Q35018167-434A85C9-FED6-4A8E-A88B-46B471E852ED

P932

Q35018167-151C18E1-224C-4C73-A683-84DF656D6799

P356

P1433

Journal of Investigative Dermatology

P1476

Epigenetic changes of EGFR hav ...... -resistant cutaneous melanomas

@en

P2093

Isaac P Witz

http://www.w3.org/2001/XMLSchema#string

Jinhua Wang

http://www.w3.org/2001/XMLSchema#string

Kelly K Chong

http://www.w3.org/2001/XMLSchema#string

Neal P Kawas

http://www.w3.org/2001/XMLSchema#string

Orit Sagi-Assif

http://www.w3.org/2001/XMLSchema#string

Sandy C Hsu

http://www.w3.org/2001/XMLSchema#string

Sharon K Huang

http://www.w3.org/2001/XMLSchema#string

Sivan Izraely

http://www.w3.org/2001/XMLSchema#string

P2860

TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer

TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

P2888

P304

532-541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/JID.2014.418

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

135

http://www.w3.org/2001/XMLSchema#string

P50

Richard A. Scolyer

Georgina V. Long

Alexander M Menzies

Diego M Marzese

P577

2014-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266028307

http://www.w3.org/2001/XMLSchema#string

P698

25243790

http://www.w3.org/2001/XMLSchema#string

P932

4307785

http://www.w3.org/2001/XMLSchema#string